معرفی
Nigel Jamieson is a Clinical Senior Lecturer within the Institute of Cancer Sciences at the University of Glasgow's School of Medicine, Dentistry & Nursing, and serves as an Honorary HPB (Hepato-Pancreato-Biliary) surgeon at Glasgow Royal Infirmary. With over 70 peer-reviewed publications, his academic career spans both clinical practice and research in pancreatic cancer, with particular focus on genomic and immunological aspects of the disease.
Dr. Jamieson's research interests center on the interaction between the genomic landscape, immune microenvironment, and chemotherapy in pancreatic cancer patients. He is developing combination therapeutic strategies targeting immune evasion mechanisms in pancreatic cancer. His work has significant implications for precision oncology approaches in gastrointestinal malignancies, particularly through his active involvement with the Precision-Panc platform, which aims to advance therapeutic development for pancreatic cancer through comprehensive molecular profiling.
Analysis of his recent publications (2024-2025) reveals a strong focus on molecular subtyping of pancreatic cancer, immune microenvironment characterization, and translational applications of genomic findings to clinical practice. His work spans multiple cancer types including pancreatic, colorectal, cholangiocarcinoma, and breast cancers, with particular emphasis on precision medicine approaches, biomarker discovery, and therapeutic targeting based on molecular characteristics.
- Clinician Scientist Fellowship by Cancer Research UK
- Lord Kelvin and Adam Smith Leadership Fellowship from the University of Glasgow
- Grants from the Academy of Sciences
- Pancreatic Cancer UK funding
Dr. Jamieson has secured significant research funding throughout his career, including grants from the Academy of Sciences and Pancreatic Cancer UK during his surgical training. His recent Clinician Scientist Fellowship from Cancer Research UK and Lord Kelvin and Adam Smith Leadership Fellowship from the University of Glasgow support his ongoing work in pancreatic cancer research. He maintains an active clinical practice while leading research initiatives that bridge surgical oncology and molecular cancer biology.
Dr. Jamieson plays a key role in the Precision-Panc platform development and management, which represents a next-generation therapeutic development platform for pancreatic cancer. His work connects basic science with clinical applications through collaborations across the University of Glasgow, Beatson Institute, and Glasgow Royal Infirmary, facilitating translational research from bench to bedside.
